Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

DaVinci Registry(Distinctly Assess Vision in Coronary Intervention)

This study has been completed.
Information provided by:
Abbott Vascular Identifier:
First received: October 21, 2005
Last updated: January 27, 2009
Last verified: January 2009

October 21, 2005
January 27, 2009
July 2003
March 2005   (final data collection date for primary outcome measure)
TVF [ Time Frame: 9 months ] [ Designated as safety issue: Yes ]
Not Provided
Complete list of historical versions of study NCT00243438 on Archive Site
  • Mode of death [ Designated as safety issue: Yes ]
  • Time to first MI [ Designated as safety issue: Yes ]
  • TVR [ Designated as safety issue: Yes ]
  • CABG [ Designated as safety issue: Yes ]
Not Provided
Not Provided
Not Provided
DaVinci Registry(Distinctly Assess Vision in Coronary Intervention)
Distinctly Access Vision In Coronary Interventions
Prospective Internet-Registry, Postmarketing-Surveillance, Registration and Follow-up of patients after Multi-Link VISION™ - Stent Implantation
A Non-Randomized prospective evaluation of the Multi-Link Rx Vision TM Coronary Stent System in the treatment of patients with De novo native coronary artery lesions
Observational Model: Cohort
Time Perspective: Prospective
Not Provided
Not Provided
Non-Probability Sample
Patients with diabetes and/or complex coronary artery disease who are treated with a Multi-Link Vision™ Stent.
Coronary Disease
Device: Multilink Vision™ Stent (CE-labeled)
Patients who have diabetes and/or complex lesions and who have had a Multilink Vision™ Stent placed.
Patients who have received a Vision stent and who have diabetes and/or complex lesions.
Intervention: Device: Multilink Vision™ Stent (CE-labeled)
Not Provided

*   Includes publications given by the data provider as well as publications identified by Identifier (NCT Number) in Medline.
March 2005
March 2005   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Women and Men Age >18 years, Intention to treat all stenosis with Multi-Link VisionTM Stents, documented patient consent

Exclusion Criteria:

  • No Multi-Link Vision™ Stent implanted, life expectation >9 M, cardiogenic shock, STEMI, NSTEMI or unstable angina pectoris with pathologic markers within the last 48 hours, intolerance of Clopidogrel/ Tiklopidin
18 Years and older   (Adult, Senior)
Contact information is only displayed when the study is recruiting subjects
Version vom 18.7.2003
Not Provided
Not Provided
Matt Kiely, Abbott Vascular
Abbott Vascular
Not Provided
Principal Investigator: Christian Hamm, MD Kerckhoff-Klinik/ Benekestr. 2-8/ 61231 Bad Nauheim
Abbott Vascular
January 2009

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP